Jazz Pharmaceuticals, Inc. and its subsidiaries, including Greenwich Biosciences, Inc.

Registered Principal Details

Business Or Interest:
Pharmaceutical manufacturing and healthcare

Lobbying Interests:
All matters affecting the pharmaceutical manufacturing and healthcare industries

CEO Name:
Bruce Cozadd
Designated Agent for Filer

Contact
JUS
Jennie U Skelton
c/o Politicom Law LLP, 28 Liberty Ship Way, Suite 2815
Sausalito, CA 94965
(415) 903-2800
(415) 610-7604
greenwichbio@politicomlaw.com
http://www.jazzpharma.com

Authorized Lobbyists

Lobbyist Name Exclusive Duties Authorized On Withdrawn On
Cassi Baker Exclusive Duties Yes Authorized On 12/29/2020 Withdrawn On 2/18/2022
Annie Early Exclusive Duties No Authorized On 12/29/2020 Withdrawn On N/A
Jeremey J Shepherd Exclusive Duties No Authorized On 12/29/2020 Withdrawn On N/A
Daniela Sharfstein Exclusive Duties No Authorized On 2/9/2022 Withdrawn On N/A

Lobbying Interests

Administrative Rulemaking Proceedings

Scheduling of FDA approved cannabidiol drugs
Agency Name
Controlled Substances Board (CSB)

Subject
Scheduling of FDA approved cannabidiol drugs

SS 121_18
For
Notification Date
5/24/2021
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.

Topics Not Yet Assigned A Bill Or Rule Number

Any legislation or rule that impacts access to Epidolex or its successor name, or cannabinol in a drug product approved by the United States Food and Drug Administration
Development, drafting or introduction of a proposal relating to
Any legislation or rule that impacts access to Epidolex or its successor name, or cannabinol in a drug product approved by the United States Food and Drug Administration

Action Intended To Affect
Both Legislative matter and rule

Notification Date
5/24/2021
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.

all matters affecting the regulation and reimbursement of CBD products and the effects on consumers
Development, drafting or introduction of a proposal relating to
all matters affecting the regulation and reimbursement of CBD products and the effects on consumers

Action Intended To Affect
Both Legislative matter and rule

Notification Date
5/24/2021
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.

Total Lobbying Effort

  2021
January - June
2021
July - December
2022
January - June
Total
Total Lobbying Expenditures 2021
January - June
$27,000.00
2021
July - December
$27,000.00
2022
January - June
$27,000.00
Total $81,000.00
Total Hours Communicating 2021
January - June
1.25
2021
July - December
0.00
2022
January - June
0.00
Total 1.25
Total Hours Other 2021
January - June
4.00
2021
July - December
3.00
2022
January - June
2.00
Total 9.00

Percent Allocation of Lobbying Effort

Legislative Bills/Resolutions

No legislative bills/resolutions found.

Budget Bill Subjects

No budget bill subjects found.

Administrative Rulemaking Proceedings

No administrative rulemaking proceedings found.

Topics Not Yet Assigned A Bill Or Rule Number

2021
January - June
2021
July - December
2022
January - June
2022
July - December
Total
2021
January - June
40 %
2021
July - December
10 %
2022
January - June
10 %
2022
July - December
Total 25 %

Minor Efforts

No minor efforts found.

Other Matters

Includes time spent on:

  • Gubernatorial nominations
  • Matters on which the organization made no lobbying communication

Other Matters
2021
January - June
2021
July - December
2022
January - June
2022
July - December
Total
2021
January - June
60 %
2021
July - December
90 %
2022
January - June
90 %
2022
July - December
Total 75 %

Filed Statements of Lobbying Activity and Expenditures